Outcome of febrile neutropenic patients treated for bacteriuria in hematology
- PMID: 36622445
- DOI: 10.1007/s00520-022-07522-4
Outcome of febrile neutropenic patients treated for bacteriuria in hematology
Abstract
Introduction: Positive urine sample is a frequent finding in post-chemotherapy febrile neutropenia (FN) and can lead to prolonged antibiotic therapy. The aim of this study was to assess the outcome of bacteriuria episodes in FN patients receiving targeted antibiotic therapy.
Materials and methods: A multi-centric retrospective study was conducted over a four-year period (2014-2019) on systematic urinalysis. All consecutive first bacteriuria episodes (≤ 2 bacteria with at least ≥ 103 CFU/mL) during FN in hospitalized adult patients for hematological malignancies were included. Relapse and recurrence were defined by fever or urinary tract symptoms (UTS) with the same bacterial subspecies in urine occurring ≤ 7 days and ≤ 30 days, respectively, after antibiotic discontinuation. Mortality rate was determined at 30 days. Targeted antibiotic therapy ≤ 10 days for women and ≤ 14 for men was considered as short course.
Results: Among 97 patients, 105 bacteriuria episodes on systematic urinalysis were analyzed; 67.6% occurred in women, 41.9% in AML patients, 17.1% were bacteremic, 14.2% presented with UTS, and 61.9% were treated with short-course antibiotic treatment. One death was reported. In men, no relapse/recurrence was noted, even in the short-course antibiotic group. In women, 2.8% of episodes treated with short-course antibiotic led to relapse or recurrence.
Conclusions: Relapse, recurrence, and mortality were uncommon events in FN patients experiencing bacteriuria episode, whatever the antibiotic duration. To distinguish asymptomatic bacteriuria from infection remained challenging in women. In men, systematic urinalysis at onset of FN could be useful.
Keywords: Asymptomatic bacteriuria; Febrile neutropenia; Hematology; Urinary tract infection.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines†. Ann Oncol 7(suppl_5):v111–8
-
- SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018) [Internet]. [cited 2019 Jun 15]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339667/
-
- Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, et al. (2013) Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica 98(12):1836–47
-
- Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis Off Publ Infect Dis Soc Am 52(4):427–431 - DOI
-
- Masaoka T (2004) Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis Off Publ Infect Dis Soc Am 15(39 Suppl 1):S49-52 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous